🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

What an amazing #BCANTT24 it was! Thx Eugene Pietzak Stephanie Chisolm, PhD Rebecca Johnson, SC members, co-chairs, speakers, pt advocates & attendees for a fantastic meeting. It was all about patients from beginning to end! Looking forward to working w/ Max Kates for planning #BCANTT25

The second #MsaouelLab R01 proposal has now been funded to investigate #RenalMedullaryCarcinoma as a model to understand and target key cancer hallmarks. This one is a multiPI collaborative effort with each team synergizing to identify unifying principles. #kidneycancer #endRMC

What a journey! Thanks Ravi A Madan M.D. and William Douglas Figg, Sr for the support and NCI Center for Cancer Research and @gulleyj1

Urachal and Nonurachal Adenocarcinomas of the Urinary Bladder: A Comprehensive Genomic Profiling Study | JCO Precision Oncology ASCO | Antonio Cigliola Chiara Mercinelli Valentina Tateo Brigida Maiorano Università Vita-Salute San Raffaele Ospedale San Raffaele UroToday.com Medscape Foundation Medicine Petros Grivas Ashish M. Kamat, MD, MBBS

Jeff Weber's career was not only filled with patient advocacy, leadership and achievement but punctuated by mentorship. I urge all fellows and junior faculty to find someone like Jeff – great friend, amazing mentor, brother, leader.  Jeff was on a trial call this Thursday at 7

Very sorry to hear of Jeff’s passing. He was the true model of the successful clinical scientist. RIP Jeff and thanks for your invaluable contributions. It was a pleasure working with you in my early day’s at Moffitt 💙🙏🏻

1/ Results from #LITESPARK-005 are out NEJM! The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) U.S. FDA approval Dec 2023 in pretreated pts w/ #ccRCC. Presentation #ESMO24 @myEsmo Check it out: nejm.org/doi/full/10.10…

Toni Choueiri, MD NEJM U.S. FDA ESMO - Eur. Oncology Guillermo de Velasco Mauricio Burotto Cris Roberto Iacovelli Brian Rini, MD Maria Carmen De Santis Fabio Schutz Laurence Albiges Charles Swanton Congrats Toni Choueiri, MD Tom Powles Laurence Albiges Brian Rini, MD and the team for this stupendous work leading to approval of belzutifan for our patients with mccRCC #kidneycancer Kidney Cancer KidneyCAN

The EMA has approved Enfortumab Vedotin and pembrolizumab for 1st line urothelial cancer. It supersedes 1st platinum based therapy as the new standard of care in Europe. astellas.com/en/news/29371?…

Barcelona 🇪🇸 #ESMO24 We Are There🚨 For Colleagues....By Colleagues #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD PhD Emre Yekedüz Hidehito HORINOUCHI Fadi Haddad, MD Dr. Iván R. González Al-Ola A Abdallah MD (USMIRC) Jose Fernando Moura, PhD Elisa Agostinetto Elisabetta Bonzano MD, PhD Eric K. Singhi, MD Bárbara Melão, MD

TROPHY-U-01 Cohort 2: Sacituzumab Govitecan achieved an ORR of 32% in cisplatin-ineligible metastatic urothelial cancer. Median PFS was 5.6 months. Main toxicities: neutropenia (34%), anemia (24%), and diarrhea (16%). #cancer #oncology OncoAlert Scott Tagawa Cora Sternberg

Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma. What is most important to patients regarding their experiences of disease burden and treatment #BladderCancer ⁦Nicholas Simon⁩ link.springer.com/article/10.100…

Just in Annals of Oncology 👉on the heels of the recent approval of belzutifan in mRCC #kidneycancer , herein we show in a ph2 randomized trial👉more belzutifan (200 mg vs 120 mg QD) was not better👇Link: tinyurl.com/nrsxp8s4 UroToday.com OncoAlert KidneyCAN Huntsman Cancer Institute

Now that EV+pembro is approved by FDA & EMA, we need to build this knowledge before prematurely defining strict criteria.

Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟 #LungCancer 🫁Abstracts to be Presented at #ESMO24 This List Curated by: #OncoAlertAF Leads Hidehito HORINOUCHI 🇯🇵 Biagio Ricciuti, MD PhD 🇺🇸 Eric K. Singhi, MD 🇺🇸 Gil Morgan, MD 🇺🇸 With our Distinguished OncoAlert 🚨Faculty

Can you please retweet, Ashish M. Kamat, MD, MBBS Petros Grivas Andrea Apolo, M.D. Dr. Bishoy M. Faltas Kent Mouw Shilpa Gupta Sam S. Chang MD, MBA Elizabeth Plimack MD Sumanta K. Pal, MD, FASCO Angie Smith Matt Nielsen, MD Sia Daneshmand, M.D.? Thank you!

Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions? Sometimes, but clinical judgement is more important than predefined criteria Andrea Apolo, M.D. Shilpa Gupta joaquim bellmunt Jonathan Rosenberg MD Michiel van der Heijden & Lisa Cordes gbr01.safelinks.protection.outlook.com/?url=https%3A%…

~1 week to #ESMO24, here is a📝 of 🔑abstracts for general onc that could change/reinforce our SoC! - #NIAGARA - #KN522 - #NATALEE - #DB12 - #MARIPOSA2 - #KRYSTAL12 - #NICHE2 - #SAKK41 - #POD1UM - #KN811 #BCSM #GISM #LCSM #MedTwitter #GUSM #OncTwitter ESMO - Eur. Oncology OncoAlert

Dr. Scott Dehm Scott Dehm Masonic Cancer Center, University of Minnesota discusses his team’s research on the biology of lethal castration resistance in #ProstateCancer including emerging underlying #genomic 🧬 understanding NCI CCR GU Malignancies GU Seminar Series NCI Center for Cancer Research National Cancer Institute

Frequency of HER2 alterations across tumor types & current development landscape of HER2-targeted therapies summarized in this publication. nature.com/articles/s4157…